OTCMKTS:IPSEY Ipsen (IPSEY) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free IPSEY Stock Alerts $33.11 +0.27 (+0.82%) (As of 05/16/2024 09:02 PM ET) Add Compare Share Share Today's Range$33.11▼$33.1150-Day Range$28.26▼$33.5252-Week Range$26.97▼$34.34Volume600 shsAverage Volume1,533 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.69%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Ipsen Stock (OTCMKTS:IPSEY)Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Read More IPSEY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSEY Stock News HeadlinesMay 14, 2024 | americanbankingnews.comIpsen S.A. (OTCMKTS:IPSEY) Sees Large Growth in Short InterestMay 7, 2024 | globenewswire.comIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General MeetingMay 2, 2024 | finance.yahoo.comIpsen appoints Keira Driansky as EVP, President of North AmericaApril 24, 2024 | msn.comIpsen S.A. reports Q1 results; reaffirms full-year guidanceApril 24, 2024 | markets.businessinsider.comIpsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial GuidanceApril 24, 2024 | finance.yahoo.comIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceApril 23, 2024 | finanznachrichten.deIpsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 22, 2024 | markets.businessinsider.comIpsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological DisordersApril 17, 2024 | finance.yahoo.comIpsen publishes its 2023 Universal Registration DocumentApril 5, 2024 | seekingalpha.comIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsApril 2, 2024 | finance.yahoo.comMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with IpsenFebruary 15, 2024 | globenewswire.comIpsen S.A. publishes its 2023 Consolidated Financial StatementsFebruary 14, 2024 | financialpost.comIpsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | finance.yahoo.comIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | msn.comIpsen gets FDA approval for pancreatic cancer drug regimenFebruary 8, 2024 | marketwatch.comIpsen Shares Fall After Forecast of Lower MarginFebruary 8, 2024 | markets.businessinsider.comBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024February 8, 2024 | markets.businessinsider.comIpsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term ViewFebruary 8, 2024 | msn.comIpsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlookFebruary 6, 2024 | finance.yahoo.comIpsen - Monthly information relative to the total number of voting rights and shares composing the share capitalJanuary 31, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In February 2024January 22, 2024 | finanznachrichten.deIpsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024January 22, 2024 | finance.yahoo.comLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024December 7, 2023 | markets.businessinsider.comIpsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease TreatmentDecember 7, 2023 | finance.yahoo.comCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlookSee More Headlines Company Calendar Today5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.99 Sales & Book Value Annual Sales$3.58 billion Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.93 Key ExecutivesMr. David Loew (Age 57)MD, CEO & Director Comp: $2.36MMr. Aymeric Le Chatelier (Age 55)Executive VP & CFO Comp: $776.95kDr. Aidan Murphy Ph.D. (Age 58)Executive VP and Head of Technical Operations Mr. Craig MarksVice-President of Investor RelationsMr. Francois Garnier (Age 62)Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer Ms. Gwenan WhiteExecutive VP and Head of Communications, Public Affairs & SustainabilityMr. Regis Mulot (Age 58)Executive VP & Chief Human Resources Officer Ms. Dominique Bery (Age 53)Head of Nordics & Baltics Mr. Bartosz Bednarz D.D.S.Executive VP and Head of Global Product & Portfolio StrategyMr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business OfficerMore ExecutivesKey CompetitorsLantheusNASDAQ:LNTHQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGIDEXX LaboratoriesNASDAQ:IDXXSolventumNYSE:SOLVView All Competitors IPSEY Stock Analysis - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPSEY shares. View IPSEY analyst ratings or view top-rated stocks. How have IPSEY shares performed in 2024? Ipsen's stock was trading at $29.48 at the start of the year. Since then, IPSEY stock has increased by 12.3% and is now trading at $33.11. View the best growth stocks for 2024 here. Are investors shorting Ipsen? Ipsen saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,200 shares, an increase of 20.0% from the April 15th total of 1,000 shares. Based on an average daily trading volume, of 1,300 shares, the days-to-cover ratio is currently 0.9 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen announced a dividend on Thursday, June 1st. Stockholders of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is a positive change from the stock's previous dividend of $0.23. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.70%. Read our dividend analysis for IPSEY. How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPSEY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist My Default Watchlist Adding Ipsen S.A. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
